- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03597126
Short Term Outcomes of Robotic-assisted Intersphincteric Resection for Low Rectal Cancer (R-ISR)
November 28, 2021 updated by: Li Chuan, Southwest Hospital, China
Short Term Outcomes of Robotic-assisted Intersphincteric Resection for Low Rectal Cancer:A Multicentric Randomized Controlled Trial
This study compared robot-assisted total mesorectal excision to treat very low rectal cancer within 2 cm from the dentate line to avoid permanent colostomy.
improves the quality of life with better defecation function, urinary function and sexual function.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tang Bo, M.D
- Phone Number: +86 13883902288
- Email: yupeiwu1961@aliyun.com
Study Contact Backup
- Name: Li Chuan, M.D
- Phone Number: +86-18323479228
- Email: lee_tran@126.com
Study Locations
-
-
-
Chongqing, China
- Recruiting
- Southwest Hospital
-
Contact:
- Yu Yupeiwu, M.D/Ph.D
- Phone Number: +8618323479228
- Email: yupeiwu01@sina.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 years < age < 80 years
- Matching the diagnostic criteria;
- tumor located 3 cm from anal verge
- Clinically diagnosed cT1-3N0-2 M0 lesions
- Tumor size of 4 cm or less
- ASA 1-3 scores;
- ECOG score is 0-1;
- Adequate preoperative sphincter function
Exclusion Criteria:
- Requiring a Mile's procedure
- Fecal incontinence;
- Previous abdominal surgery
- Severe mental disease.
- Intolerance of surgery for severe comorbidities
- Emergency operation due to complication
- Pregnant woman or lactating woman
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: robot-assisted ISR
Patients with low rectal cancer undergo intersphincteric resection assisted by Robotic
|
robot-assisted intersphincteric resection for low location rectal cancer(T=1&2)
|
|
Active Comparator: laparoscopic ISR
Patients with low rectal cancer undergo laparosocopic intersphincteric resection
|
laparoscopic intersphincteric resection for low location rectal cancer(T=1&2)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in urinary function
Time Frame: 6 months
|
The days of indwelling catheter after operation The overall efficiency of urination function
|
6 months
|
|
Change in International Index of Erectile Function [IIEF] score
Time Frame: 18 months
|
Alterations in IIEF scores from baseline up to 18 months postoperatively - 15 item questionnaire, each item range from 0 - 5, with total score to 30.
lower score indicates more severe erectile dysfunction (ED)
|
18 months
|
|
Change in FIQL scores
Time Frame: 18 months
|
Alterations in Fecal Incontinence Quality of Life Instrument (FIQL) scores from baseline up to 18 months postoperatively - 29 items range from 1 (strongly agree) to 4 (strongly disagree); with a 1 indicating a lower functional status of quality of life.
Scale scores are only calculated if at least half of the items have been answered
|
18 months
|
|
Change in Female Sexual Function Index [FSFI]
Time Frame: 18 months
|
Alterations in FSFI from baseline up to 18 months postoperatively - 19-item self-report measure, each item ranges from 0-5, with full range from 2 to 36, with low score indicating sexual function disorder.
|
18 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2018
Primary Completion (Anticipated)
June 1, 2022
Study Completion (Anticipated)
December 1, 2022
Study Registration Dates
First Submitted
April 23, 2018
First Submitted That Met QC Criteria
July 13, 2018
First Posted (Actual)
July 24, 2018
Study Record Updates
Last Update Posted (Actual)
December 9, 2021
Last Update Submitted That Met QC Criteria
November 28, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RoboticISR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.